Literature DB >> 100820

Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drug (flupenithixol) in rats.

E B Nielsen, M Lyon.   

Abstract

The number of nerve cells in two different areas of the corpus striatum (i.e., ventrolateral and dorsomedial) was estimated in rat brain after long-term (36 weeks) treatment with the neuroleptic flupenthixol. Nine rats were given weekly injections of 4 mg/kg flupenthixol dissolved in Viscoleo i.m., and seven rats received Viscoleo alone. Fourteen to 18 weeks after the last drug injection, the animals were decapitated and half of each brain was fixated with formalin for cell-count analysis and the remaining half used for a biochemical analysis (Nielsen, 1977). Separate cell counts in the ventrolateral and dorsomedial corpus striatum yielded a significant cell loss of approximately 10%, but only in the ventrolateral striatum of treated animals. These results suggest at least one concrete anatomical basis for the behavioral and biochemical deficits found in the same animals, as reported earlier. The results further suggest that persistent irreversible anatomical changes can follow long-term neuroleptic treatment. The inconsistencies of results regarding cell loss in the corpus striatum may be due to neglect of dorsal-ventral structural differences in corpus striatum.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 100820     DOI: 10.1007/bf00428036

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  Comparison of the effects of neuroleptic drugs on pre- and postsynaptic dopaminergic mechanisms in the rat striatum.

Authors:  L L Iversen; M A Rogawski; R J Miller
Journal:  Mol Pharmacol       Date:  1976-03       Impact factor: 4.436

2.  Deficits in consummatory responses to regulatory challenges following basal ganglialesions in rats.

Authors:  D B Neill; C L Linn
Journal:  Physiol Behav       Date:  1975-05

3.  The precise localization of nigral afferents in the rat as determined by a retrograde tracing technique.

Authors:  B S Bunney; G K Aghajanian
Journal:  Brain Res       Date:  1976-12-03       Impact factor: 3.252

4.  Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia.

Authors:  J Gerlach; N Reisby; A Randrup
Journal:  Psychopharmacologia       Date:  1974-01-09

5.  Behavioral effects of amphetamine in rats with lesions in the corpus striatum.

Authors:  D B Neill; W O Boggan; S P Grossman
Journal:  J Comp Physiol Psychol       Date:  1974-06

6.  The long-term effect of perphenazine enanthate on the rat brain. Some metabolic and anatomical observations.

Authors:  H Pakkenberg; R Fog; B Nilakantan
Journal:  Psychopharmacologia       Date:  1973

7.  Neostriatum and functions of prefrontal cortex.

Authors:  I Divac
Journal:  Acta Neurobiol Exp (Wars)       Date:  1972       Impact factor: 1.579

8.  Attenuation of self-stimulation from substantia nigra but not dorsal tegmental noradrenergic bundle by lesions of sulcal prefrontal cortex.

Authors:  R M Clavier; M E Corcoran
Journal:  Brain Res       Date:  1976-08-20       Impact factor: 3.252

9.  Movement disorders induced in monkeys by chronic haloperidol treatment.

Authors:  B Weiss; S Santelli; G Lusink
Journal:  Psychopharmacology (Berl)       Date:  1977-08-16       Impact factor: 4.530

10.  Long-term behavioural and biochemical effects following prolonged treatment with a neuroleptic drug (flupenthixol) in rats.

Authors:  E B Nielsen
Journal:  Psychopharmacology (Berl)       Date:  1977-10-20       Impact factor: 4.530

View more
  15 in total

1.  Study of neuropathologic changes in the striatum following 4, 8 and 12 months of treatment with fluphenazine in rats.

Authors:  D V Jeste; J B Lohr; M Manley
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics.

Authors:  I Maurer; H J Möller
Journal:  Mol Cell Biochem       Date:  1997-09       Impact factor: 3.396

3.  Effects of chronic haloperidol and/or clozapine on oxidative stress parameters in rat brain.

Authors:  Fabiano R Agostinho; Luciano K Jornada; Nadja Schröder; Rafael Roesler; Felipe Dal-Pizzol; João Quevedo
Journal:  Neurochem Res       Date:  2007-03-31       Impact factor: 3.996

4.  Reversal of haloperidol-induced orofacial dyskinesia by quercetin, a bioflavonoid.

Authors:  Pattipati S Naidu; Amanpreet Singh; Shrinivas K Kulkarni
Journal:  Psychopharmacology (Berl)       Date:  2003-04-01       Impact factor: 4.530

5.  Neuroleptic induced parkinsonism: MRI findings in relation to clinical course after withdrawal of neuroleptic drugs.

Authors:  V Bocola; G Fabbrini; A Sollecito; C Paladini; N Martucci
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-02       Impact factor: 10.154

6.  Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms.

Authors:  Pattipati S Naidu; Amanpreet Singh; Shrinivas K Kulkarni
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

7.  Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol.

Authors:  C K Meshul; O A Andreassen; C Allen; H A Jørgensen
Journal:  Psychopharmacology (Berl)       Date:  1996-06       Impact factor: 4.530

8.  Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats.

Authors:  Santhrani Thaakur; G Himabindhu
Journal:  J Neural Transm (Vienna)       Date:  2009-05-15       Impact factor: 3.575

9.  Cytotoxic effects of neuroleptic drugs.

Authors:  W H Munyon; R Salo; D F Briones
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

10.  Effect of spirulina maxima on the haloperidol induced tardive dyskinesia and oxidative stress in rats.

Authors:  S R Thaakur; B Jyothi
Journal:  J Neural Transm (Vienna)       Date:  2007-05-26       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.